(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 2.64% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.03%.
Phibro Animal Health's revenue in 2024 is $982,014,000.On average, 2 Wall Street analysts forecast PAHC's revenue for 2024 to be $40,269,213,621, with the lowest PAHC revenue forecast at $40,110,317,966, and the highest PAHC revenue forecast at $40,428,109,275. On average, 2 Wall Street analysts forecast PAHC's revenue for 2025 to be $41,970,446,164, with the lowest PAHC revenue forecast at $41,904,222,765, and the highest PAHC revenue forecast at $42,036,669,563.
In 2026, PAHC is forecast to generate $43,473,251,531 in revenue, with the lowest revenue forecast at $43,473,170,524 and the highest revenue forecast at $43,473,332,539.